Diagnoly
Diagnoly helps clinicians improve prenatal screening by providing real‑time AI analysis of fetal ultrasound to detect abnormalities and ensure complete exams. It builds Fetoly, a DeepTech B2B SaaS and medical device that uses AI and deep learning models integrated with ultrasound systems to provide on‑device, real‑time feedback during scans. Fetoly analyzes anatomical landmarks, detects over 100 fetal abnormalities, validates exam completeness against ISUOG guidelines, and automates repetitive measurements to increase consistency. The solution runs locally on mobile devices and remains compatible with major ultrasound platforms without requiring cloud services, preserving clinical data control. Diagnoly targets obstetricians and healthcare providers and holds FDA clearance for Fetoly‑Heart and CE marking for fetal heart and brain analysis.
Diagnoly
Diagnoly helps clinicians improve prenatal screening by providing real‑time AI analysis of fetal ultrasound to detect abnormalities and ensure complete exams. It builds Fetoly, a DeepTech B2B SaaS and medical device that uses AI and deep learning models integrated with ultrasound systems to provide on‑device, real‑time feedback during scans. Fetoly analyzes anatomical landmarks, detects over 100 fetal abnormalities, validates exam completeness against ISUOG guidelines, and automates repetitive measurements to increase consistency. The solution runs locally on mobile devices and remains compatible with major ultrasound platforms without requiring cloud services, preserving clinical data control. Diagnoly targets obstetricians and healthcare providers and holds FDA clearance for Fetoly‑Heart and CE marking for fetal heart and brain analysis.
TL;DR
Product: Fetoly — on-device, real-time AI for fetal ultrasound (landmarking, QA, anomaly detection)
Regulatory: FDA clearance for Fetoly-Heart and CE marking for fetal heart and brain analysis
Founded: 2020 — Lyon, France
Latest funding: Seed round announced Apr 8, 2025 (€5.5M reported)
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |
Company Overview
Problem Domain
Prenatal fetal ultrasound quality assurance and anomaly detection
Founded
2020
Industry
Medical Equipment Manufacturing
Funding Track Record
€5.5M
Reported seed round announced Apr 8, 2025; participants include Mutuelles Impact, Newfund and existing investor BAdGE
Profiles list multiple prior funding events and non-equity assistance but details not specified in evidence
Investor Signal
“Mutuelles Impact and Newfund participate as lead investors in the Seed round; additional investors reported across rounds include XAnge, Les Business Angels des Grandes Écoles, WorldUpstart, Angelor, MassChallenge Switzerland”